170 likes | 353 Views
2014 “ Towards an HIV Cure ” symposium Melbourne. A novel assay that precisely measures the size of the latent HIV reservoir reveals that ART-naïve individuals harbour a large pool of latently infected CD4+ T cells Nicolas Chomont, PhD. Measuring the size of the reservoir.
E N D
2014 “Towards an HIV Cure” symposiumMelbourne A novel assay that precisely measures the size of the latent HIV reservoir reveals that ART-naïve individuals harbour a large pool of latently infected CD4+ T cells Nicolas Chomont, PhD
Measuring the size of the reservoir • There is currently no gold standard method to measure the size of the latent HIV reservoir (frequency of latently infected cells) • The quantitative viral outgrowth assay measures replication-competent HIV but may largely underestimate the size of the reservoir (Ho, Cell 2013) • PCR based assays are reproducible, relatively easy to perform but may overestimate the size of the reservoir (Eriksson, Plos Pathogens 2013) There is a need to develop sensitive, reproducible and clinical trial scalable methods to measure the size of the latent HIV reservoir
Defective viral genomes Ho et al. Cell 2013
Principle of TILDA TILDA: “Tat/Rev Induced Limiting Dilution Assay” Frequency of cells with msHIV RNA baseline Ficoll gradient centrifugation Negative selection Nested RT-PCR for msHIV RNA (24+40 cycles) 10-20 mL whole blood CD4+ T cells Distribute in limiting dilutions Maximum likelihood method PBMCs Frequency of cells with inducible msHIV RNA 12h PMA+ionomycin
TILDA in CD4 T cells from ART subjects The majority of cells with inducible virus are latently infected in ART subjects
TILDA and other assays TILDA gives a reservoir size in between Q-VOA and DNA Adapted from Eriksson et al. 2013
TILDA and other assays Total DNA in PBMCs Total DNA in resting CD4 Integrated DNA in PBMCs Integrated DNA in resting CD4 Total DNA in rectal CD4 Q-VOA SCA TILDA correlates with several assays measuring HIV persistence
ART in Acute and Chronic infection TILDA distinguishes between subjects who have started ART during acute and chronic infection
TILDA in viremic subjects (no ART) The majority of cells with inducible virus are latently infected in ART naive subjects
TILDA in viremic subjects (no ART) ART VIR 75% of the cells with inducible HIV are latently infected in untreated HIV infected subjects
Pre-integration latency? Entry Uncoating Reverse transcription Viral production Integration Viral transcription Post-integration latency Pre-integration latency
Pre-integration latency? TILDA PMA+ionomycin + Post-integration latency RALTEGRAVIR (4h) PMA+ionomycin + RALTEGRAVIR + PMA+ionomycin Pre-integration latency + RALTEGRAVIR (4h) PMA+ionomycin + RALTEGRAVIR -
TILDA with raltegravir VIR1 VIR9 VIR11 Post-integration latency is already established in untreated HIV-infected subjects
Conclusions • TILDA is: • sensitive(1.4 cells/million) • reproducible (coefficient of variation <0.2) • fast(<2 days) • relatively inexpensive($300) • easily transferable(basic culture set up + real time PCR) • Clinical trial transferable(requires only 10mL of blood) • The median frequency of “reservoir” cells measured by TILDA is 24 cells/million, which is 48 times more than Q-VOA and 6 to 27 times less than PCR-based assays • In untreated disease, the frequency of latently infected cells largely exceeds the frequency of productively infected cells suggesting that the majority of infected cells are transcriptionally silent even in the absence of ART • This provides a rationale for the use of shock and kill strategies at the time of ART initiation
Shock and kill at ART initiation shock ART HIV viral load HIV-specific CD8 T cells Latent reservoir ART
Acknowledgements Westmead Institute Sarah Palmer Karolinska Institutet Susanne Eriksson University of Pennsylvania Una O’Doherty Johns Hopkins Robert Siliciano Janet Siliciano UCSD Doug Richman Matt Strain U19AI096109 R21AI113096 ARCHE 108687-54 The study participants! VGTI Florida Francesco Procopio RemiFromentin Deanna Kulpa Amanda McNulty Anne-Gaelle Blackwell LydieTrautmann Rafick-Pierre Sekaly Merck and Co DariaHazuda Mike Miller Richard Barnard UCSF Steven Deeks Rick Hecht